Amexis G - Search Results

1

Detection of a point mutation in poliovaccines with a water soluble carbodiimide reaction of DNA heteroduplexes.

Amexis G, Bertling WM, Löwer J. Amexis G, et al. Dev Biol Stand. 1996;86:325. Dev Biol Stand. 1996. PMID: 8785965 No abstract available.

2

Stability of the prion protein-encoding (PRNP) gene in HeLa cells.

Amexis G, Ridge J, Cervenakova L, Enterline JC, Chumakov KM, Asher DM. Amexis G, et al. Biologicals. 2003 Mar;31(1):83-6. doi: 10.1016/s1045-1056(02)00069-6. Biologicals. 2003. PMID: 12623063

3

Correlation of genetic variability with safety of mumps vaccine Urabe AM9 strain.

Amexis G, Fineschi N, Chumakov K. Amexis G, et al. Virology. 2001 Aug 15;287(1):234-41. doi: 10.1006/viro.2001.1009. Virology. 2001. PMID: 11504558 Free article.

4

Sequence diversity of Jeryl Lynn strain of mumps virus: quantitative mutant analysis for vaccine quality control.

Amexis G, Rubin S, Chizhikov V, Pelloquin F, Carbone K, Chumakov K. Amexis G, et al. Virology. 2002 Sep 1;300(2):171-9. doi: 10.1006/viro.2002.1499. Virology. 2002. PMID: 12350348 Free article.

5

Quantitative mutant analysis of viral quasispecies by chip-based matrix-assisted laser desorption/ ionization time-of-flight mass spectrometry.

Amexis G, Oeth P, Abel K, Ivshina A, Pelloquin F, Cantor CR, Braun A, Chumakov K. Amexis G, et al. Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):12097-102. doi: 10.1073/pnas.211423298. Epub 2001 Oct 2. Proc Natl Acad Sci U S A. 2001. PMID: 11593021 Free PMC article.

6

Changes in mumps virus gene sequence associated with variability in neurovirulent phenotype.

Rubin SA, Amexis G, Pletnikov M, Li Z, Vanderzanden J, Mauldin J, Sauder C, Malik T, Chumakov K, Carbone KM. Rubin SA, et al. Among authors: amexis g. J Virol. 2003 Nov;77(21):11616-24. doi: 10.1128/jvi.77.21.11616-11624.2003. J Virol. 2003. PMID: 14557647 Free PMC article.

7

Identification of a new genotype H wild-type mumps virus strain and its molecular relatedness to other virulent and attenuated strains.

Amexis G, Rubin S, Chatterjee N, Carbone K, Chumakov K. Amexis G, et al. J Med Virol. 2003 Jun;70(2):284-6. doi: 10.1002/jmv.10392. J Med Virol. 2003. PMID: 12696119

8

Targeted Therapies, Novel Antibodies, and Immunotherapies in Advanced Non-Small Cell Lung Cancer: Clinical Evidence and Drug Approval Patterns.

Koban MU, Hartmann M, Amexis G, Franco P, Huggins L, Shah I, Karachaliou N. Koban MU, et al. Among authors: amexis g. Clin Cancer Res. 2024 Nov 1;30(21):4822-4833. doi: 10.1158/1078-0432.CCR-24-0741. Clin Cancer Res. 2024. PMID: 39177967 Free PMC article. Review.

9

Clinical Development and Initial Approval of Novel Immune Checkpoint Inhibitors in Oncology: Insights From a Global Regulatory Perspective.

Serrano P, Hartmann M, Schmitt E, Franco P, Amexis G, Gross J, Mayer-Nicolai C. Serrano P, et al. Among authors: amexis g. Clin Pharmacol Ther. 2019 Mar;105(3):582-597. doi: 10.1002/cpt.1123. Epub 2018 Sep 12. Clin Pharmacol Ther. 2019. PMID: 29923615 Review.

10

A sponsor's experience with the Voluntary Harmonization Procedure for clinical trial applications in the European Union.

Amexis G, Schmitt E. Amexis G, et al. Nat Rev Drug Discov. 2011 May;10(5):393. doi: 10.1038/nrd3202-c1. Nat Rev Drug Discov. 2011. PMID: 21532569 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13 results

Search Page

Filters